Every intervention Outliyr has scored for liver health, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for liver health; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
46 of 86 evaluated interventions score 3.0+ out of 10 for liver health · 15 comparisons
The liver-detox use case for Tirzepatide scores 8.3/10, reflecting meta-analysis data that show meaningful weight loss and reductions in insulin resistance, key drivers of MASLD/MASH risk Franco 2025. Tirzepatide's dual GIP/GLP-1 agonism…
Read the Tirzepatide report →NAC earns 8.0/10 for liver and detoxification because its single most-proven use is hepatoprotection: as the FDA antidote for acetaminophen overdose it cuts hepatotoxicity to about 6.1 percent when started within 10…
Read the NAC (N-Acetylcysteine) report →For liver-detox, Retatrutide lands at 8.0/10 because Rosenstock 2023 supports the strongest part of the claim. The existing rationale points to this narrower claim: The glucagon receptor arm is designed to raise…
Read the Retatrutide report →Glycine liver detox earns 7.6/10 because Soh 2024 anchors the most relevant signal. Glycine fits liver detox because glycine participates in sleep signaling, glutathione, collagen, methylation, and nervous-system balance, depending on the…
Read the Glycine report →Berberine fits liver detox at 7.5/10 when the baseline problem is real. Yan 2015 tested berberine in NAFLD, and Nie 2024 pooled 10 RCTs in 811 NAFLD patients with improvements in liver…
Read the Berberine report →Semaglutide scores 7.5/10 for liver-detox because Sanyal 2025 strengthened the phase 3 MASH case after Newsome 2021 showed NASH-resolution benefit. The phrase liver-detox is imperfect here; this is really metabolic liver disease…
Read the Semaglutide report →Thymosin Alpha-1 liver detox earns 7.0/10 because Tian 2025 anchors the most relevant signal. Thymosin Alpha-1 fits liver detox when immune modulation is medically relevant and monitored rather than casually guessed. The…
Read the Thymosin Alpha-1 report →Population fit explains the 7.0/10 liver detox score for Ketogenic Diet because the evidence points to a plausible use case without proving a universal response. Eshaghhosseiny Z et al. 2024 is the…
Read the Ketogenic Diet report →For users targeting liver support, Taurine earns 6.8/10 because Tzang 2024 reports 25 RCTs and 1024 participants; lower SBP, DBP, fasting blood glucose, and triglycerides; no significant adverse-effect excess. Tzang 2024 points…
Read the Taurine report →Mechanistically, Molecular Hydrogen fits liver support at 6.5/10 because Kang 2011 reports Hydrogen-rich water improved quality-of-life and oxidative-stress direction during liver-tumor radiotherapy without reducing tumor response. Ohta 2011 points in the same…
Read the Molecular Hydrogen report →BPC-157 liver detox earns 6.5/10 because Vasireddi 2025 anchors the most relevant signal. BPC-157 fits liver detox when the target is tissue repair, vascular recruitment, or inflammation control, but the case still…
Read the BPC-157 report →TUDCA scores 6.5/10 for liver detox because the most direct human evidence concerns hepatobiliary disease, bile acids, and liver-related endpoints rather than vague detox language. Pan 2013 studied TUDCA in liver cirrhosis,…
Read the TUDCA (Tauroursodeoxycholic Acid) report →Evidence puts Tesamorelin at 6.5/10 for liver detox, mainly through Falutz et al. 2007. HIV-associated fatty liver data support a meaningful liver-fat signal. Stanley 2019 tested tesamorelin in HIV-associated NAFLD, and Fourman…
Read the Tesamorelin report →Liver disease is survodutide's strongest case. In a 48-week biopsy-confirmed Phase 2 trial, 62% of patients on 4.8 mg saw their fatty liver disease (MASH) improve with no worsening of scarring, versus…
Read the Survodutide (BI 456906) report →The liver detox case for Omega-3 lands at 6.0/10 because the evidence points to a plausible use case without proving a universal response. Abuknesha et al. 2025 is the best anchor here…
Read the Omega-3 report →Detoxification is the strongest single sulforaphane signal in humans. Egner 2014 Qidong RCT in 291 Chinese adults showed urinary benzene conjugate excretion increased 61 percent and acrolein conjugate excretion increased 23 percent…
Read the Sulforaphane report →The liver case sits at 6.0/10 because Yarmohammadi 2021 pooled 8 RCTs and found AST fell 9.15 U/L (95% CI -16.09 to -2.21), a significant signal, while ALT and ALP did not…
Read the Chlorella report →The liver case scores 6.0/10 because the liver holds the body's highest glutathione concentration and runs the Phase II conjugation that glutathione enables. The most direct human signal is Honda 2017, an…
Read the Glutathione (GSH) report →Liver fat clearance is the most differentiated thing mazdutide does. Reported reductions run roughly 72 to 80 percent in participants with high baseline liver fat, with the GLORY-1 high-baseline subgroup near 80…
Read the Mazdutide (IBI362) report →A 5.5/10 for liver-detox fits Zone 2 Cardio because Vabishchevich 2026 supports direction more than certainty. The existing rationale points to this narrower claim: Zone 2 can reduce hepatic fat through improved…
Read the Zone 2 Cardio report →Liver health scores 5.5/10 because the NAFLD signal is suggestive but thin. Mazloomi 2022 ran a randomized double-blind trial in 46 NAFLD patients using 20 g/day for 8 weeks and reported significant…
Read the Spirulina report →Metformin's liver-detox use-case scores 5.5 / 10, reflecting modest evidence such as the UKPDS trial that showed metformin lowers hepatic glucose output in overweight diabetics UK Prospective Diabetes Study Group 1998. Metformin…
Read the Metformin report →Spermidine's 5.2/10 liver-detox score starts with Kiechl 2018, then gets narrowed by the evidence gap. The existing rationale points to this narrower claim: this verified source supports liver fibrosis and hepatocellular-carcinoma prevention…
Read the Spermidine report →For users targeting liver support, Essential Amino Acids earns 5.0/10 because Hagiyama 2024 reports 12 RCTs; 622 patients; low-certainty improvement in patient-reported outcomes and very-low-certainty strength signal after lower-limb surgeries. Wittholz 2024…
Read the Essential Amino Acids report →Ca-AKG (Calcium Alpha-Ketoglutarate)'s 5.0/10 liver-detox score starts with Filip 2007, then gets narrowed by the evidence gap. The existing rationale points to this narrower claim: No direct liver-detox evidence. AKG participates in…
Read the Ca-AKG (Calcium Alpha-Ketoglutarate) report →Liver support scores 5.0 out of 10 on the strength of repeated animal hepatoprotection data. Zhou 2018 found Pinus massoniana pollen polysaccharides lowered AST, ALT, ALP, and MDA dose-dependently in CCl4-challenged rats,…
Read the Pine Pollen report →The evidence base for SLU-PP-332 liver-detox is limited to a single pre-clinical study that reported a roughly 20 % improvement in hepatic steatososis markers in mice with metabolic syndrome Billon 2024. SLU-PP-332…
Read the SLU-PP-332 report →No direct liver-detox evidence. Circulation and sweating claims should not be translated into liver clearance or toxin-elimination claims.
Read the Whole-Body Vibration report →Liver support scores 4.5/10. The NAC component is the proven antidote that restores hepatic glutathione in acetaminophen overdose, validating the detoxification pathway, but GlyNAC as a combination has no dedicated liver-outcome trial,…
Read the GlyNAC (Glycine + N-Acetylcysteine) report →Liver enzymes were stable to improved in human dosing studies, and ergothioneine concentrates in the liver, but dedicated hepatic-outcome trials are absent. No detox framing.
Read the Ergothioneine report →Preserved v0.x score. Detox positioning is not supported by verified clinical outcomes. Mechanistic liver-protection ideas come from oxidative-preconditioning literature summarized by Sagai and Bocci 2011, but no human trial in the audit…
Read the Ozone Therapy report →The TANGO trial (Chooi 2024, n=88, 12 weeks) supports an Asian-adapted Mediterranean diet for fatty liver and suggests C15:0 may add a small adjunctive signal, including LDL-cholesterol and gut-microbiome shifts. The main…
Read the C15 (Pentadecanoic Acid) report →There is an irony here. Curcumin improves liver enzymes and fat markers in NAFLD trials, yet enhanced-absorption forms are the ones linked to rare idiosyncratic liver injury. For fatty-liver support the signal…
Read the Curcumin report →INSUFFICIENT_EVIDENCE for liver detoxification; hepatic enzymes are monitoring targets because of metabolism and safety, not expected benefit.
Read the Rapamycin report →Liver scores 4.0/10 and cuts both ways: coffee polyphenols associate with lower liver-disease and fibrosis risk in cohorts, but high-dose isolated green-tea catechin extracts carry a rare idiosyncratic hepatotoxicity signal. Whole-food intake…
Read the Polyphenols (Dietary) report →The MASLD meta-analysis by Arslan 2025 suggests preliminary liver enzyme, lipid, and inflammation improvements with quercetin in MASLD adults, but the synthesis is new and study counts and bias profiles are still…
Read the Quercetin report →Hepatoprotective preclinical data exists, but human liver-outcome evidence remains weak and v1.0 avoids detox framing.
Read the Astaxanthin report →Modest, indirect liver benefit through weight loss and falling ALT, but no dedicated fatty-liver program.
Read the Orforglipron (Foundayo) report →Modern testosterone routes avoid the severe hepatotoxicity associated with older methylated oral anabolic steroids. Still, liver enzymes, lipids, alcohol use, and product selection need monitoring, especially with oral formulations.
Read the TRT (Testosterone Replacement Therapy) report →Liver and detox claims remain weak. Akbari 2020 found no significant effect on ALT or AST in metabolic-syndrome-related RCTs, despite a small total-cholesterol signal and increased GGT. Human NAFLD translation has been…
Read the Resveratrol report →A small calcium-butyrate trial in metabolic-associated fatty liver showed some benefit, but it is underpowered and not replicated.
Read the Sodium Butyrate report →Exercise improves hepatic fat metabolism and metabolic health, but the report avoids detox language beyond liver-fat and metabolic markers.
Read the Norwegian 4×4 report →LiverTox lists Tongkat Ali as a rare possible cause of clinically apparent liver injury, while standardized-extract trials have not shown consistent liver-enzyme problems. This is a caution score, not a detox claim.
Read the Tongkat Ali report →Hepatoprotective signals are preclinical only; no human liver-outcome evidence and v2.0 avoids detox framing.
Read the Fucoidan (Brown Seaweed Polysaccharide) report →Hataguchi 2005 noted lower hair levels of toxic minerals, but this is not a controlled detoxification endpoint and the report avoids detox framing.
Read the Quinton Marine Plasma (Seawater Minerals) report →Hepatoprotective preclinical data for chaga and reishi triterpenes, but the one notable human liver signal is a fatal powdered-reishi hepatitis case report, so the human picture is cautionary, not protective.
Read the Adaptogenic Mushrooms (Reishi, Cordyceps, Chaga) report →Nothing matches those filters.
Head-to-head reports and category rankings that name a winner on this use case.
Tirzepatide, at 6.1, then semaglutide at 6.0, then orforglipron at 5.8 if you want the pill. All three are approved, all three have real trial evidence, and all…
No. Berberine scores 6.8 and semaglutide 6.0, and that gap misleads almost everyone who reads it. Berberine scores higher because it is cheap, oral and easy to stop,…
BPC-157 for structural repair, KPV for inflammation you cannot afford to stimulate. BPC-157 scores gut health 9.0 against KPV's 7.0 and wins nearly every other row, because it…
No. Omega-3 scores 6.8 and C15:0 4.9, and the evidence gap is larger than the score gap. C15:0 has two small human trials. Omega-3 has outcome trials, prescription…
Tesamorelin, unless price is the only thing deciding. It is FDA-approved for visceral fat with Phase 3 trials behind it, while CJC-1295 is a gray-market research peptide whose…
Different jobs, same shelf. Quercetin scores 6.8 and curcumin 6.5, which decides nothing. Curcumin wins joints, inflammatory markers, gut and mood. Quercetin wins allergies, blood pressure, uric acid…
Sulforaphane scores 6.8 and glutathione 6.2, and both have a delivery problem. Sulforaphane needs active myrosinase or you absorb half as much. Plain oral glutathione barely raises blood…
Different liver problems. NAC scores 8.0 and TUDCA 6.7, and NAC wins liver detox 8.0 against 6.5, but its liver evidence is toxin and oxidative damage. TUDCA owns…
Metformin scores 6.9 and berberine 6.8, so the gap is meaningless. Metformin owns blood sugar with decades of outcome trials behind it. Berberine owns fatty liver, needs no…
NAC scores 8.0 and glutathione 6.2, and that gap is real. NAC is the cheaper upstream precursor with a six-decade clinical record, so start there. Glutathione earns its…
Start tirzepatide. It scores 6.1 against retatrutide's 5.6, and the gap is mostly availability and evidence maturity rather than weaker biology. Retatrutide is not approved anywhere, cannot legally…
Spirulina scores 7.0 and chlorella 6.5, so spirulina is the better default for most people. It leads on blood pressure, blood sugar, inflammation and breathing. Chlorella leads on…
Tirzepatide, at 8.3 out of 10 for liver health. The liver-detox use case for Tirzepatide scores 8.3/10, reflecting meta-analysis data that show meaningful weight loss and reductions in insulin resistance, key drivers of MASLD/MASH risk Franco 2025.
Of the top-scoring options, Glycine is the least expensive at about $2 a month, scoring 7.6 out of 10 for liver health.
46 of the 86 interventions evaluated for liver health score 3.0 out of 10 or better, which is the cut-off for appearing on this page.
